Adicet Bio, Inc. Common Stock (ACET) is a publicly traded Healthcare sector company. As of May 21, 2026, ACET trades at $7.95 with a market cap of $70.11M and a P/E ratio of -0.79. ACET moved +7.59% today. Year to date, ACET is -4.79%; over the trailing twelve months it is -35.28%. Its 52-week range spans $6.01 to $24.64. Analyst consensus is strong buy with an average price target of $34.83. Rallies surfaces ACET's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Adicet Bio doubles prula-cel enrollment to 20+ patients, secures $74.8M and FDA outpatient dosing: Adicet Bio doubled prula-cel Phase 1 enrollment to over 20 patients by December 31, 2025 and secured FDA agreement for outpatient SLE and LN dosing. The company raised $74.8 million and plans a pivotal prula-cel study plus ADI-212 regulatory filing in H1 2026, extending its cash runway into H2 2027.
| Metric | Value |
|---|---|
| Price | $7.95 |
| Market Cap | $70.11M |
| P/E Ratio | -0.79 |
| EPS | $-9.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $24.64 |
| 52-Week Low | $6.01 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $682.93M |
| Net Income | $-346.15M |
| Gross Margin | 12.76% |
7 analysts cover ACET: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $34.83.